Last reviewed · How we verify
Ceftazidime± avibactam with fosfomycin
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin provides additional cell wall disruption through a distinct mechanism.
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin provides additional cell wall disruption through a distinct mechanism. Used for Multidrug-resistant gram-negative bacterial infections, including carbapenem-resistant Enterobacteriaceae (CRE), Complicated urinary tract infections and intra-abdominal infections caused by resistant pathogens.
At a glance
| Generic name | Ceftazidime± avibactam with fosfomycin |
|---|---|
| Also known as | CAZ±AVI + FOS, InfectoFos® |
| Sponsor | Angela HUTTNER |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination with fosfomycin |
| Target | Penicillin-binding proteins (PBPs), beta-lactamases, and MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that binds penicillin-binding proteins and inhibits bacterial cell wall cross-linking. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation by resistant organisms. Fosfomycin is a phosphonic acid antibiotic that inhibits MurA, an early step in peptidoglycan synthesis, providing synergistic bactericidal activity against multidrug-resistant gram-negative bacteria.
Approved indications
- Multidrug-resistant gram-negative bacterial infections, including carbapenem-resistant Enterobacteriaceae (CRE)
- Complicated urinary tract infections and intra-abdominal infections caused by resistant pathogens
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
- Elevated liver enzymes
Key clinical trials
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
- Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (PHASE4)
- PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
- Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftazidime± avibactam with fosfomycin CI brief — competitive landscape report
- Ceftazidime± avibactam with fosfomycin updates RSS · CI watch RSS
- Angela HUTTNER portfolio CI